primary biliary cirrhosis: Primary biliary cholangitis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
106 |
4. Check minimum number of eventsNone |
106 |
5. Include endpointsNone |
106 |
6. Filter based on genotype QC (FinnGen only) |
100 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- K74
- Name in latin
- Cirrhosis biliaris non specificata
Similar endpoints
↥List of similar endpoints to
Biliary cirrhosis, NAS
based on the number of shared cases.
Similar with more cases:
- Fibrosis and cirrhosis of liver
- Diseases of liver
- Gastrointestinal diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 740 | 440 | 291 |
| Only index persons | 591 | 365 | 226 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 66.30 | 67.90 | 64.08 |
| Only index persons | 65.48 | 66.47 | 63.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 100 | 66 | 34 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 64.71 | 64.44 | 65.24 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 106
- Matched controls
- 1060
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K74.5
ICD-10 Finland
Biliary cirrhosis, unspecified
+∞
152.9
106
*
A05AA02
ATC
ursodeoxycholic acid; oral
251.2
75.0
70
8
K74.3
ICD-10 Finland
Primary biliary cirrhosis
391.2
61.1
56
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
18.5
53.6
62
75
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
75.7
38.3
42
9
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
9.9
26.8
39
59
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
45.0
26.5
32
10
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
8.1
23.1
41
77
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.2
19.5
69
244
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
45.6
18.5
22
6
JJ1LE
NOMESCO Finland
Ultrasound elastography of liver
93.4
15.0
16
*
C03DA01
ATC
spironolactone; oral
5.3
13.9
36
93
C03CA01
ATC
furosemide; systemic
4.2
12.0
64
283
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
73.3
11.9
13
*
R18
ICD-10 Finland
Ascites
20.6
11.1
16
9
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.0
10.6
21
42
K76.9
ICD-10 Finland
Liver disease, unspecified
29.3
10.1
13
5
I85.0
ICD-10 Finland
Oesophageal varices with bleeding
60.7
9.8
11
*
A07EA06
ATC
budesonide; oral, local oral
12.4
9.7
17
16
L04AX01
ATC
azathioprine; systemic
13.2
9.4
16
14
TJJ00
NOMESCO Finland
Percutaneous needle biopsy of liver
97.5
8.5
9
*
K73.2
ICD-10 Finland
Chronic active hepatitis, not elsewhere classified
97.5
8.5
9
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
14.6
8.1
13
10
K73.9
ICD-10 Finland
Chronic hepatitis, unspecified
48.7
7.8
9
*
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
48.7
7.8
9
*
ZX120
NOMESCO Finland
Intravenous
4.1
7.8
25
74
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
14.8
7.6
12
9
K74.0
ICD-10 Finland
Hepatic fibrosis
85.8
7.5
8
*
K75.4
ICD-10 Finland
Autoimmune hepatitis
+∞
7.4
7
*
K83.0
ICD-10 Finland
Cholangitis
21.9
7.3
10
5
M05BA04
ATC
alendronic acid; oral
4.0
7.0
23
69
UJF32
NOMESCO Finland
Coloscopy
3.0
7.0
46
215
L04AA06
ATC
mycophenolic acid; systemic
18.2
6.9
10
6
M34.1
ICD-10 Finland
CR(E)ST syndrome
42.9
6.9
8
*
A06AD11
ATC
lactulose; oral
3.4
6.8
30
110
C10AC01
ATC
colestyramine; oral
12.1
6.5
11
10
JCA22
NOMESCO Finland
Endoscopic ligature of oesophageal varices
28.5
6.3
8
*
L04AD02
ATC
tacrolimus; systemic
28.5
6.3
8
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
28.5
6.3
8
*
5716A
ICD-9 Finland
Chronic liver disease and cirrhosis, Biliary cirrhosis[CIRRHOSIS BILIARIS PRIMARIA]
+∞
6.3
6
*
UJF30
NOMESCO Finland
Ileoscopy through colon
3.9
6.1
20
60
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
16
22.15
18.62
3.9
2.0
10.74
234.47
u/ml
0.46
27
16
18
11
19.38
12.17
1.6
1.1
—
—
—
0
0
81
471
4.05
9.21
21.9
14.4
1.25
1.24
inr
0.06
35
143
13
10
14.60
8.12
1.9
1.6
—
—
—
0
0
81
497
3.67
7.91
13.4
6.8
1.20
1.22
mmol/l
0.82
63
416
49
237
2.99
7.00
3.6
2.1
4.25
3.22
mg/l
0.97
43
207
16
25
7.34
6.96
1.8
1.6
—
—
—
0
0
80
525
3.14
6.23
13.7
9.4
4.22
4.19
e9/l
0.02
72
452
73
462
2.86
5.97
12.5
5.9
1.20
1.21
mmol/l
0.80
66
421
14
24
6.55
5.76
2.3
1.9
—
—
—
0
0
62
366
2.67
5.74
4.4
2.6
135.93
123.43
ug/l
0.12
57
331
37
175
2.71
5.27
9.5
3.4
0.78
0.82
mmol/l
1.19
37
165
10
12
9.06
5.19
2.1
2.1
—
—
—
0
0
25
99
3.00
4.91
1.7
1.9
—
—
—
0
0
32
146
2.71
4.84
1.8
1.9
—
—
—
0
0
25
101
2.93
4.73
1.8
1.9
—
—
—
0
0
17
63
3.02
3.70
3.4
1.7
—
—
—
0
0
8
13
6.55
3.57
1.1
1.3
—
—
—
0
0
6
6
10.49
3.54
1.0
1.0
—
—
—
0
0
8
14
6.08
3.41
5.1
2.0
57.38
63.29
%
—
8
14
38
222
2.11
3.16
3.8
2.3
—
—
—
0
0
25
123
2.35
3.14
3.8
4.7
2.93
10.38
ug/l
1.37
19
104
7
12
6.16
3.07
1.0
1.4
—
—
—
0
0
9
21
4.58
3.07
1.3
1.1
—
—
—
0
0
8
18
4.71
2.85
1.1
1.5
—
—
—
0
0
52
354
1.92
2.74
3.9
3.4
2.30
2.36
mmol/l
1.28
46
308
8
19
4.46
2.74
2.6
1.4
—
—
—
0
0
5
7
7.42
2.57
3.0
1.9
0.68
0.87
g/l
—
5
7
13
51
2.77
2.55
1.9
2.0
—
—
—
0
0
5
8
6.49
2.40
2.2
1.6
—
—
—
0
0
58
425
1.81
2.31
6.1
2.6
—
—
—
0
0
23
125
2.07
2.25
8.6
6.5
-0.82
1.48
mmol/l
1.23
16
105
8
24
3.52
2.23
1.4
1.6
—
—
—
0
0
8
24
3.52
2.23
1.1
1.5
—
—
—
0
0
8
24
3.52
2.23
1.1
1.5
—
—
—
0
0
55
401
1.77
2.19
4.4
4.0
66.17
34.19
ng/l
0.37
47
309
33
208
1.85
2.11
2.3
1.7
1243.62
1205.25
nmol/l
0.08
24
151
12
50
2.58
2.11
6.3
5.0
1.06
1.94
mmol/l
—
7
38
21
115
2.03
2.01
5.4
3.9
—
—
—
0
0
41
284
1.72
1.89
5.0
3.2
0.53
0.46
e6/l
0.10
31
219
6
17
3.67
1.86
1.7
1.3
—
—
—
0
0
30
191
1.80
1.84
1.5
1.2
1.96
0.71
u/ml
—
9
50
7
23
3.18
1.83
1.1
1.1
—
—
—
0
0
11
48
2.44
1.77
1.2
1.3
—
—
—
0
0
12
55
2.33
1.75
6.3
4.7
4.50
4.95
kpa
1.01
12
55
22
130
1.87
1.70
8.4
6.4
105.73
104.02
mmol/l
1.23
22
130
8
31
2.71
1.70
1.1
1.2
—
—
—
0
0
5
15
3.44
1.54
1.0
1.1
—
—
—
0
0
36
254
1.63
1.50
3.9
2.7
360.17
5205.98
umol/l
1.29
30
211
46
346
1.58
1.48
5.2
3.2
—
—
—
0
0
25
165
1.67
1.34
3.6
2.8
0.86
0.96
e6/l
0.08
13
93
10
49
2.15
1.26
1.9
2.3
1.13
1.31
%
—
10
49
5
20
2.57
1.16
1.0
1.4
—
—
—
0
0
12
66
1.92
1.14
11.8
8.8
93.32
94.33
%
0.43
12
66
23
157
1.59
1.08
3.7
3.1
2.10
3.31
e6/l
—
10
85
7
35
2.07
1.02
4.3
2.2
—
—
—
0
0
55
459
1.41
0.96
6.4
5.6
0.00
0.00
estimate
-0.00
12
90
6
28
2.21
0.93
3.8
2.4
21.82
24.33
mmol/l
—
6
28
8
43
1.93
0.89
3.5
4.2
23.98
24.96
mmol/l
—
8
43
12
72
1.75
0.89
26.7
6.0
23.39
24.71
mmol/l
0.49
12
72
6
30
2.06
0.88
1.5
1.9
—
—
—
0
0
33
255
1.43
0.87
5.9
4.4
0.00
0.00
estimate
-0.00
14
90
48
397
1.38
0.86
2.4
2.0
86.39
98.39
pmol/l
1.14
27
175
6
32
1.93
0.83
1.5
2.2
—
—
—
0
0
54
461
1.35
0.77
5.5
4.1
0.00
0.00
estimate
-0.00
15
97
5
26
1.97
0.71
1.4
1.5
—
—
—
0
0
7
44
1.63
0.66
3.4
3.6
37.10
48.73
%
—
7
44
81
747
1.36
0.62
51.7
20.2
16.13
15.32
%
0.80
81
735
26
205
1.36
0.60
2.0
3.1
2.52
2.47
mmol/l
1.34
19
178
53
466
1.27
0.56
5.9
4.1
0.00
0.00
estimate
-0.00
14
82
7
49
1.46
0.47
1.1
1.2
—
160.12
—
0
15
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
3.9
—
85.98
—
0
16
15
117
1.33
0.38
1.6
1.5
—
—
—
0
0
50
456
1.18
0.33
2.8
2.7
—
—
—
0
0
35
312
1.18
0.29
2.0
2.0
78.77
160.45
u/l
4.44
35
293
14
113
1.28
0.28
1.1
1.3
—
—
—
0
0
32
284
1.18
0.28
5.4
3.9
11.99
6.93
mg/mmol
0.55
22
168
86
827
1.21
0.27
4.8
5.0
2.37
1.93
mu/l
0.68
78
732
40
366
1.15
0.24
5.6
4.3
—
—
—
0
0
70
666
1.15
0.23
4.1
4.2
15.11
14.92
pmol/l
0.21
62
589
10
123
0.79
0.21
12.8
6.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
3.00
—
0
5
87
844
1.17
0.20
35.8
15.8
71.48
76.17
ml/min/173m2
1.09
72
691
17
187
0.89
0.11
2.6
4.7
32.23
21.94
%
—
6
96
5
45
1.12
0.10
1.2
1.8
—
—
—
0
0
27
253
1.09
0.10
1.3
1.7
1.53
1.25
mmol/l
1.21
22
208
6
56
1.08
0.09
2.2
1.4
—
—
—
0
0
88
869
1.07
0.05
4.7
4.8
1.38
1.52
mmol/l
1.91
79
775
86
871
0.93
0.05
5.4
5.0
6.27
5.97
mmol/l
0.97
75
782
88
870
1.07
0.04
4.9
4.9
4.21
4.61
mmol/l
2.74
79
783
86
852
1.05
0.02
7.4
6.2
41.22
40.50
mmol/mol
0.22
80
783
84
834
1.03
0.00
4.6
4.3
1.30
1.24
mmol/l
0.32
75
737
89
894
0.97
0.00
5.3
5.5
2.33
2.67
mmol/l
3.69
81
800
96
955
1.06
0.00
59.9
23.8
37.69
39.61
%
2.20
90
890
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
236.11
—
0
9
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
23.20
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
74.28
—
0
6
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHIRBIL_NAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHIRBIL_NAS | 4.689 [3.16, 6.97] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.134 |
During the follow-up period (1.1.1998 — 31.12.2019), 149 out of 349 females with CHIRBIL_NAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHIRBIL_NAS | 5.621 [3.23, 9.79] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 207 males with CHIRBIL_NAS died.
Mortality risk
Mortality risk for people of age
years, who have CHIRBIL_NAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.314% | 1.206% |
| 5 | 2.226% | 6.182% |
| 10 | 6.182% | 15.232% |
| 15 | 11.143% | 27.835% |
| 20 | 19.285% | 44.691% |
Relationships between endpoints
↥Index endpoint: CHIRBIL_NAS – Biliary cirrhosis, NAS
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data